Legalization of Medical Cannabis and Potential Implications for Healthcare Delivery in the United States by Cornett, Lauren N
Kentucky Journal of Undergraduate Scholarship
Volume 2 | Issue 1 Article 2
6-1-2018
Legalization of Medical Cannabis and Potential
Implications for Healthcare Delivery in the United
States
Lauren N. Cornett
Eastern Kentucky University, lauren_cornett27@eku.edu
Follow this and additional works at: https://encompass.eku.edu/kjus
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Journals at Encompass. It has been accepted for inclusion in Kentucky Journal of
Undergraduate Scholarship by an authorized editor of Encompass. For more information, please contact Linda.Sizemore@eku.edu.
Recommended Citation
Cornett, Lauren N. (2018) "Legalization of Medical Cannabis and Potential Implications for Healthcare Delivery in the United States,"
Kentucky Journal of Undergraduate Scholarship: Vol. 2 : Iss. 1 , Article 2.
Available at: https://encompass.eku.edu/kjus/vol2/iss1/2
Legalization of Medical Cannabis and Potential Implications for
Healthcare Delivery in the United States
Cover Page Footnote
The author would like to thank Dr. Jennifer Hight, OTD, OTR/L for her continued mentorship throughout
the research process.
This article is available in Kentucky Journal of Undergraduate Scholarship: https://encompass.eku.edu/kjus/vol2/iss1/2
LEGALIZATION OF MEDICAL CANNABIS
1
Legalization of Medical Cannabis and Potential 
Implications for Healthcare Delivery in the United 
States
Abstract: Cannabis legalization is currently a topic of significant 
interest within the American healthcare system. Existing research 
has demonstrated the effects of medical cannabis in alleviating 
manifestations of several common health conditions which affect 
many Americans, including cancer and chronic pain. Additionally, 
research has demonstrated that medical cannabis programs have 
positive implications for the objectives of government health 
initiatives such as the Institute for Healthcare Improvement (IHI) 
Triple Aim. Economic benefits from cannabis taxation have also 
been documented in states with active medical cannabis programs. 
While federal restrictions inhibit extensive cannabis research, 
the legalization of medical cannabis has significant implications 
for the American healthcare system in terms of cost, access, and 
quality. This paper is a review of current literature and research 
regarding medical cannabis legalization in the United States. 
Keywords: healthcare, cannabis, medical cannabis, United States
The issue of legalizing cannabis for medical use has become one of 
the top-discussed health topics in recent years. With 27 states and the District 
of Columbia participating in active medical cannabis programs, much of the 
movement’s effort is now focused on developing arguments to persuade 
the remaining states to implement similar legislation. The legalization 
of cannabis for both medical and recreational purposes has benefits and 
drawbacks, but this paper will focus on support for medicinal legalization.
History and Current Status of Legalization
 The use of cannabis, or marijuana, for medicinal purposes dates 
back to the 15th century, when the first written mention of the drug was 
found in an ancient Chinese medical book, the Rh-Ya (Historical Timeline, 
2017). In the United States, marijuana was a common prescription for a 
variety of health conditions until 1937, when the Marihuana Tax Act of 
1937 effectively criminalized and prohibited the drug (Historical Timeline, 
2017). Since then, numerous advocacy groups, politicians, and social 
movements have attempted to expand the legalization of marijuana for both 
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legalization as a stepping stone to full legalization, and rightfully so. Recent 
research has shown marijuana to be effective in managing manifestations 
of numerous health conditions that are among the most prevalent in 
America, including cancer, HIV/AIDS, chronic pain, and glaucoma 
(Bradford & Bradford, 2016), and with less harmful effects than some 
commonly-prescribed pharmaceuticals. As it currently stands, national and 
state legislature are significantly divided on the topic of medical cannabis 
legalization. At the national level, possession of marijuana for any purpose 
is still illegal, meaning that patients in possession of the drug in medically-
legal states could still potentially incur criminal charges on the federal level 
(Johannigman & Eschiti, 2013). This discrepancy stems in part from the 
federal classification of marijuana as a Schedule I drug, which the Controlled 
Substances Act of 1970 defines as having “no currently acceptable medical 
use in treatment in the United States, a high potential for abuse, and a lack 
of accepted safety for use under medical supervision (Bradford & Bradford, 
2016).” This classification places cannabis in the same category of opiates 
such as heroin and morphine (Controlled Substances Act) and significantly 
inhibits the cultivation and acquisition of cannabis for prescriptive use and 
for further research on its effects in treating various health conditions. From 
what little cannabis research has been done, considerable implications have 
been found for two health issues currently at the forefront of the American 
healthcare field: cancer and opioid overdose. 
Relevance to National and Community Health
Cancer. According to the Center for Disease Control, cancer is the 
second leading cause of death in the United States, claiming nearly 600,000 
lives in 2015. In the state of Kentucky alone, there were over 10,000 deaths 
from cancer in 2015, making it the state’s leading cause of death (“Cancer 
Rates by U.S. State,” 2016). In states with operational medical cannabis 
programs, cancer is a qualifying condition for prescription, and use of the 
drug as it has proven effective in managing side effects of chemotherapy 
such as nausea, loss of appetite, and pain (Johannigman and Eschiti, 
2013). Additionally, a 2014 study by Scott, Dalgleish, and Liu found that 
tetrahydrocannabinol (THC), the major active component of cannabis, 
reduced the size of certain cancer cells and inhibited the process of cell 
proliferation by interfering with cell communication mechanisms (Scott et 
al., 2014). While the results of this particular study only discovered these 
properties in glioma cells, the data “add further support to the concept 
that cannabinoids both alone and in combination with each other, possess 
anticancer properties” (Scott et al., 2014).
Opioid overdose. The second prominent national and community 
health issue pertaining to medical cannabis legalization is opioid overdose. 
While illegal opioids such as heroin were responsible for nearly 13,000 
deaths in the United States in 2015, over 15,000 of the nation’s opioid-related 
deaths in the same year were caused by prescription opioids alone (National 
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Center for Health Statistics, 2017). These prescription opioids include 
methadone, oxycodone, and hydrocodone, and are usually prescribed to 
patients with chronic pain, a common health condition in the United States. 
According to an investigation by Bachhuber et al. (2014), chronic pain is 
also the primary indication for medical cannabis prescription in states with 
active laws. Subsequent research found that in states with medical cannabis 
laws, the mean annual rate of opioid overdose was 24.8% lower than in 
states without medical cannabis laws. From these results, it is predicted that 
“patients with chronic [noncancer] pain who would have otherwise initiated 
opioid analgesics may choose medical cannabis instead” (Bachhuber et al., 
2014), and therefore contribute to lower rates of prescription opioid overdose 
and death. If substantiated by further research, these findings could prove 
to be significant for Kentucky in particular; according to the Overdose 
Fatality Report released by the Kentucky Office of Drug Policy, over 1,000 
Kentuckians die from drug overdose per year (Tilley & Ingram, 2015). 
Among the most commonly detected drugs in these cases were morphine 
(45%), fentanyl (34%), oxycodone (23%), and hydrocodone (21%), all of 
which are commonly prescribed analgesic opioids (Tilley & Ingram, 2015). 
While the research on these health issues has strong implications, it lacks 
volume; current federal legislation regarding medical marijuana inhibits its 
accessibility for clinical and scientific research. The legalization of medical 
marijuana on a federal level would eliminate these barriers and allow for 
more thorough and interdisciplinary research on the effects of cannabis on 
cancer, opioid overdose, and an array of other health conditions, making 
this an important healthcare issue on both national and community levels 
in the United States. In addition, the legalization of medical cannabis could 
have significant impacts on central concepts of the U.S. healthcare delivery 
framework as well.
Impact on Healthcare Delivery and Impacted Populations
The three cornerstones of the healthcare delivery system are cost, 
access, and quality (Shi & Singh, 2015). 
Cost. In the realm of healthcare, cost carries a different meaning 
based on the perspective from which it is viewed; consumers and providers 
place cost into a “price” context, while government defines it as “national 
expenditures.” While research on the “price” of medical cannabis is limited 
due to lack of cannabis accessibility, some research has been done on the 
impact of medical cannabis on national healthcare expenditures. In a 2016 
study, Bradford & Bradford performed an analysis of Medicare Part D 
spending data for prescription drugs from 2010 to 2013. The researchers 
limited the analysis to drugs prescribed for conditions for which medical 
marijuana is considered an alternative method of treatment: anxiety, 
depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders, 
and spasticity. The study’s results indicated that in states with active 
medical marijuana policies, all of the conditions except glaucoma had fewer 
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drug prescriptions written than in states without legal medical marijuana. 
This translated to a Medicare Part D and enrollee spending reduction of 
$165.2 million in 2013 when totaled across the 17 states and the District 
of Columbia, all of which had legal medical marijuana laws at that time 
(Bradford & Bradford, 2016). If all states had had active medical marijuana 
laws in 2013, the study projected that Medicare Part D expenditures would 
have been reduced by $468.1 million (Bradford & Bradford, 2016). 
Access. The cornerstone of access refers to “the ability of a person to 
obtain health care services when needed” (Shi and Singh, 2015). Access is 
considered “one of the key determinants of health” (Shi and Singh, 2015), and 
is a valuable assessment tool in evaluating the effectiveness of a healthcare 
delivery system.  In the case of medical cannabis, access is fragmented and 
inconsistent due to varying state policies and federal restrictions. Medical 
marijuana patients, as well as healthcare practitioners, who live in legalized 
states are still subject to criminal possession charges, and face difficulty 
accessing the drug in other states due to varying requirements and approved 
indications. As summarized by J. Michael Bostwick, MD. (2012),
 Without a federal umbrella, regulations lack any state-to-state 
uniformity about what constitutes acceptable indications, appropriate 
prescriber-patient relationships, or legitimate means of acquiring botanical 
cannabis…physicians who prescribe medical marijuana are susceptible to 
prosecution under the same statutes as drug dealers.
Legalizing medical cannabis on a national level would provide 
consistent regulations across all states, thereby increasing access to medical 
cannabis for all patient populations with approved indications. 
Quality. The third cornerstone, quality, is defined as “the degree to 
which health services for individuals and populations increase the likelihood 
of desired health outcomes and are consistent with current professional 
knowledge” (Shi and Singh, 2015). Despite the emerging research 
evidencing positive health effects of medical cannabis, many medical and 
legislative professionals remain staunchly opposed. Much of this hesitation 
comes from assumption that medical cannabis must be smoked in order to 
be effective and the negative implications that may have one one’s health; in 
the words of Johannigman and Eschiti, “Smoking of any substance has been 
linked to lung cancer, which carries the highest mortality rate of any cancer 
type in the United States” (2013). While marijuana smoke inhalation is the 
most common method of usage and the quickest way to experience its effects 
(“How Marijuana is Consumed”, 2016), the lung and throat irritation and 
damage caused can make certain health conditions worse. Oral consumption 
of marijuana, or “edibles”, is often preferred by medicinal patients; chronic 
pain patients in particular have reported that the effects of orally ingested 
marijuana last longer, reducing the number of doses required to achieve pain 
relief (“How Marijuana is Consumed”, 2016). For more superficial health 
conditions such as muscle pain, stiffness, swelling, and neuralgia, topical 
cannabis products can be applied in the form of cream, lotion, or salve. The 
cannabinoids in the topical product interact with CB1 and CB2 receptors 
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in the skin, providing pain relief and anti-inflammatory effects without 
the psychoactive effects associated with inhaled and ingested cannabis 
(“Cannabis 101”, 2016). Topical administration of cannabis is often popular 
with older adult populations due to its effective management of localized 
pain and lack of psychoactive effects (“Cannabis 101”, 2016). Overall, 
the various forms of marijuana ingestion allow for healthier alternatives 
to chemical medication, and the positive effects of the drug that have been 
revealed through research could improve the quality of life for countless 
Americans and Kentuckians alike. 
Current federal restrictions limit opportunities for medical marijuana 
prescription and clinical research. However, legalization of medical cannabis 
would provide regulations for the cultivation and production of cannabis 
and cannabis byproducts, which would provide populations such as chronic 
pain patients, cancer patients, and older adults with the safest and highest 
quality form of medical cannabis for their specific health conditions and 
needs. Therefore, legalization of medical cannabis has significant positive 
implications for the facets of cost, access, and quality within the American 
healthcare delivery system.
Applications
As previously addressed, research suggests that the healthcare 
delivery cornerstones of cost, access, and quality could face significant 
alterations with the legalization of medical cannabis. In a similar vein, 
medical cannabis legalization has positive potential implications for each 
objective within the Institute for Health Improvement (IHI) Triple Aim. The 
objectives of the IHI Triple Aim are experience of care, population health 
and per capita cost (“The IHI Triple Aim”, 2016). 
Experience of care. In a study by Reiman (2008), patient care 
experience ratings from 130 adult medical cannabis patients were collected 
via questionnaire and analyzed. The results of the study yielded an 80% or 
higher satisfaction rating in three of the four satisfaction dimensions, which 
included General, Interpersonal, Access, and Privacy satisfaction (Reiman, 
2008, p.35). These results indicate that the interdisciplinary services of 
medical cannabis programs improve patient healthcare experience; as stated 
by Reimer (p. 40), “the social support offered to medical cannabis patients 
provides an escape and a way to cope.” 
Population health. As referenced in the Relevance to National 
and Community Health section, medical cannabis has been shown to be 
effective in managing two of the most prominent health concerns in the 
United States: cancer and opioid addiction. In addition, research by Reimer 
(2008) suggests that medical cannabis programs improve population 
health by implementing a more holistic approach to patient care. Reimer 
acknowledges the positive effects of social support and teaching of healthy 
coping mechanisms on patient satisfaction, stating that “primary physical 
and mental health services might have a better chance of achieving their 
intended effect if clients are receiving additional social support and coping 
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services” (p. 40).
Per capita cost. While current national policies restrict the scope 
of research on medical cannabis and per capita cost in the United States, 
economic benefits have been observed in states with active medical cannabis 
programs. In particular, research has highlighted benefits in the arenas of 
Medicare Part D spending and taxation profits. A study by Bradford & 
Bradford (2013) attributes the reduction in Medicare Part D spending to 
fewer pharmaceutical prescriptions in states with active medical cannabis 
programs. Significant taxation revenue has also been noted in these states. 
A review of 2016 Tax Foundation Reports showed that Colorado, a state 
with one of the most established medical cannabis programs, collected 
approximately $140 million in marijuana taxes in 2016 (Ekins & Henchman, 
2016). 
Application to Occupational Science
Through the lens of occupational science, the legalization of medical 
cannabis would also fulfill the ideal of occupational justice. Nilsson and 
Townsend (2010) define occupational justice as “a justice that recognizes 
occupational rights to inclusive participation in everyday occupations for 
all persons in society, regardless of age, ability, gender, social class, or other 
differences.” Occupational injustice, or situations in which occupational 
justice is absent, takes several different forms; occupational deprivation is 
a form of occupational injustice which connects to the legal ramifications 
surrounding medical cannabis. According to Whiteford (2003), occupational 
deprivation is “a state of prolonged preclusion from engagement in 
occupations of necessity and/or meaning due to factors that stand outside 
the control of the individual.” In the case of medical cannabis patients, the 
inconsistencies and legal restrictions of the medical cannabis industry pose 
potential difficulties in terms of acquiring the needed dosages, accessing 
proper cannabis products such as edible forms and topical substances, and 
legal protection in states where medical cannabis is not yet legal. As such, 
there could be situations in which chronic pain patients, cancer patients, or 
patients with a number of other health conditions cannot gain access to their 
source of symptom management. This could result in acute manifestations 
of symptoms such as pain, nausea, vomiting, and loss of appetite, making 
it difficult if not impossible for these patients to participate in activities of 
daily living, leisure activities, and social participation. 
Application to Healthcare Practitioner Role
As healthcare practitioners, a significant part of those roles is to 
advocate for clients and their rights and needs. Investigating topics such 
as the legalization of medical cannabis and its implications for healthcare 
delivery in America is an important educational opportunity as it is a 
current and highly controversial issue that is becoming a prevalent topic of 
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discussion in political, academic, and medical arenas.
Relevance
Relevance to Current Policies
In the political, academic, and medical realms, policies are 
constantly changing and modifying to include new regulations, restrictions, 
and penalties. Additionally, public health and safety policies are constantly 
adapting to accommodate medical cannabis as new states begin to consider 
its legalization. As the first state in the nation to have legalized both 
medical and recreational cannabis (Ghosh et al., 2016), the public health 
framework of Colorado has been studied and serves as a valuable reference 
for states desiring to implement similar policies. To improve consistency 
and effectiveness of its policies, Colorado has adopted a multidisciplinary 
approach to working on cannabis-related issues; experts from a variety 
of public agencies such as human services, public safety, education, and 
health care work together to establish regulations for cannabis production 
and distribution that both “respect the intention of the voters while striving 
to mitigate negative outcomes (Ghosh et al., 2016).” One of the key 
components and core values of Colorado’s policy development is education 
(Ghosh et al., 2016), to which end they implemented the “Good to Know 
Colorado” campaign. The campaign’s purpose is to provide educational 
messages and materials to the residents of Colorado regarding safe, legal, 
and responsible marijuana use; this includes information about secondhand 
smoke reduction, combining marijuana with other substances, and the 
dangers of using marijuana while underage (Ghosh et al., 2016). The 
“Good to Know Colorado” campaign is reminiscent of other public policy 
education efforts nationwide, and is an invaluable component of the public 
health framework. The Colorado policymakers report that one of the most 
significant challenges to their work has been discord between local, state, 
and federal laws regarding cannabis. A reference to limited potential for 
research is made in their report; “Research to assess both the beneficial 
and the adverse health effects of marijuana’s Schedule I drug designation 
applied by the U.S Drug Enforcement Agency (Ghosh et al., 2016).”
Implications for Healthcare Delivery
The legalization of medical marijuana would carry many positive 
implications for the healthcare delivery system. With legalization on a 
national level, federal regulations could be implemented to streamline the 
medical cannabis industry, product cultivation, and product distribution, 
ultimately making the drug more accessible to a larger patient population. 
Further research on cannabis’s effects on health conditions such as cancer 
and chronic pain could substantiate current research findings, and increased 
prescription of medical cannabis could reduce Medicare Part D spending and 
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private insurance costs in the pharmaceutical realm. Overall, the utilization 
of medical marijuana as an intervention for pain and symptom management 
demonstrates significant implications for improved patient quality of life as 
evidenced by current research.
Consequences for Healthcare Delivery
In addition to the consequences of reducing healthcare costs, 
increasing accessibility, and increasing overall patient quality of life, the 
legalization of medical cannabis is a potential source of significant revenue 
at both state and federal levels. According to a 2016 Tax Foundation report, 
states with full legalization of marijuana have seen revenue collections 
that far exceeded their initial projections; Colorado, anticipating an annual 
collection of $70 million in marijuana tax, was on track to collect over $140 
million by the end of 2016 (Ekins & Henchman, 2016). The report predicts 
that if all states legalized cannabis, there would be a collective revenue of 
$5 billion to $18 billion per year (Ekins & Henchman, 2016). On a federal 
level, the report proposes that an excise tax on marijuana similar to that on 
cigarettes would yield $500 million in revenue, while a 10% sales tax on 
cannabis products is projected to raise $5.3 billion (Ekins & Henchman, 
2016).
Conclusion
Current research supports the idea that nationwide legalization 
of medical cannabis would offer improvements to the three healthcare 
cornerstones of cost, access, and quality. In short, medical cannabis 
legalization would lower healthcare expenditures on pharmaceuticals, 
increase accessibility of the drug to include a larger patient population, and 
improve overall patient quality of life by offering cannabis in various forms 
for use. The public health policy frameworks of legalized states such as 
Colorado can be taken into consideration when developing federal and state 
policies and regulations. Medical cannabis legalization has implications to 
increase tax revenue on individual state and federal levels, and government 
regulations would work to streamline the cultivation, production, and 
distribution of cannabis and its byproducts. With full legalization, jobs 
would be created within the industry in the form of farming, production, 
and dispensary positions. Client and caregiver education, much like the 
“Good to Know Colorado” campaign, are crucial in order to promote safe, 
legal, and responsible cannabis use. While the issue of medical marijuana 
legalization is controversial, the research presented within this document 
strongly suggests that further investigation is warranted and has significant 
implications for improvements within the healthcare delivery system.
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